Latest From Biopure Corp.
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.
OPK Biotech, a US subsidiary of the Luxembourg-based OPK Luxadvor owned by Sergei Pugachev, one of Russia's oligarchs, is to acquire the assets of Biopure Corporation, a troubled US biotech company, at a recent bankruptcy court auction in Boston. Biopure filed for chapter 11 bankruptcy protection in the US on July 16th, when its total debt had reached $2.7 million and its assets were worth an estimated $5.1 million.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Biopure Corp.
- Senior Management
Zafiris G Zafirelis, Pres. & CEO
David A Butler, CFO
Virginia T Rentko, VP, Preclinical Dev.
Barry Scott, VP, Bus. Dev.
- Contact Info
Phone: (617) 234-6500
11 Hurley St.
Cambridge, MA 02141
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.